Obesity Clinical Trial
Official title:
Single Dose Pharmacokinetics of Intravenous Tedizolid Phosphate in Morbidly Obese and Age-, Sex-, and Ideal Body Weight-Matched Non-Obese Adults
This is an open label, single-dose, pharmacokinetic study in 9 obese and 9 age-, sex-, ideal body weight- matched non-obese subjects. Qualifying subjects who have completed an informed consent will receive a single intravenous dose of tedizolid with the collection of 11 blood samples over 72 hours post dose.
Subjects will present to the clinical research unit in the morning (approximately 6:30 a.m.)
of the dosing day. A urine pregnancy test will be performed to rule out pregnancy prior to
administration of the tedizolid phosphate dose to female subjects. The subject's height,
total body weight, and vital signs (heart rate, blood pressure, temperature, and respiratory
rate) will be recorded. Subjects judged (by study physician) to be healthy enough to
participate will proceed with the study procedures.
An 18-20 gauge intravenous peripheral catheter will be inserted into the antecubital vein or
a vein in the fore-arm of the non-dominant arm for sequential blood sampling, and an initial
predose blood sample (5 mL) will be collected. A minimum of 3-5 mL of blood is required per
pharmacokinetic sampling time-point. Each blood collection tube will be pre-labeled with:
1.) study protocol number; 2.) subject study number; 3.) date of collection; 4.) time-point.
A 0.9% Sodium Chloride infusion may be run through the peripheral line at 30 to 40 mL per
hour to maintain catheter patency for the 12 hour sampling phase. Alternatively, a heparin
lock technique will be utilized to maintain intravascular catheter patency.
A single-dose of tedizolid phosphate will be administered as an intravenous infusion (250 mL
normal saline) over 1 hour (~8:00 a.m.). The intravenous administration tubing will be
flushed with 0.9% Sodium Chloride infusion at 250 mL per hour (to match the tedizolid
phosphate rate of infusion) for 10 minutes to ensure complete dose delivery. Blood samples
(5 mL) will be collected 0.5 (middle of infusion), 1 (end of infusion), 2, 4, 6, 8, 12, 24,
48, and 72 hours post dose in blood collection tubes. The plasma will be harvested
(centrifugation at 4°C) within 60 minutes of collection and stored at -70°C as two aliquots
until analysis. The intravascular catheter "dead-space" volume will be discarded prior to
blood sample collection by withdrawing 1.5-2 mL from the catheter to ensure no unintentional
sample dilution. The intravascular catheter will be removed after the 12 hour sample and the
subject will be discharged from the research unit. The subject will return to the research
unit for blood sample collection on a daily basis at the following points: 24 (Visit 3), 48
(Visit 4), and 72 hours (Visit 5) after the dose via a peripheral vein needle stick. The
exact date and time of blood sample collection will be recorded on case report forms. Each
blood sample tube will be inverted and made up-right 5 times to afford mixing of blood with
the anticoagulant. Blood samples will be maintained on wet ice and centrifuged at 1200 g for
10 minutes at 4°C within 60 minutes of collection to yield approximately 2 mL of plasma per
5 mL blood collection. The plasma samples will be transferred from the -20°C freezer for
storage at -70°C at the end of the sample collection period until analysis.
;
Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |